Minocyclin in Ulcerative Colitis as Added on Therapy (NCT06201793) | Clinical Trial Compass
CompletedPhase 2
Minocyclin in Ulcerative Colitis as Added on Therapy
Egypt46 participantsStarted 2024-01-22
Plain-language summary
Ulcerative colitis (UC) is considered a subcategory of inflammatory bowel disease and the exact cause of ulcerative colitis remains undetermined. the condition appears to be related dysregulated immune response and consequent activation of inflammatory cascades, which are often affected by genetic susceptibility and environmental factors, and 20% to 40% of patients with UC also exhibit extraintestinal manifestations involving the joints, skin, eyes, or hepatobiliary tract
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Age ≥ 18 years old Both male and female will be included Mild and moderate UC patients diagnosed and confirmed by endoscope Patient treated with 5-aminosalislic acid (mesalamine)
Exclusion Criteria:
Patients with severe UC Pregnancy and lactating females Significant liver and kidney function abnormalities Diabetic patients Patients with Colorectal cancer patients Patients taking rectal or systemic steroids Patients on immunosuppressants or biological therapies Patients taking antacids, anticoagulants, bactericidal antibiotics, oral contraceptives, and isotretinoin.
Addiction to alcohol and / or drugs Known allergy to the studied medications History of complete or partial colectomy.
What they're measuring
1
Assessment of disease activity using Partial Mayo Scoring Index